Wall Street analysts expect that ViewRay, Inc. (NASDAQ:VRAY) will announce earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks. Two analysts have issued estimates for ViewRay’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.16). ViewRay posted earnings of ($0.35) per share during the same quarter last year, which would suggest a positive year over year growth rate of 60%. The company is expected to announce its next quarterly earnings results on Monday, November 13th.
On average, analysts expect that ViewRay will report full-year earnings of ($0.81) per share for the current year, with EPS estimates ranging from ($0.90) to ($0.66). For the next financial year, analysts expect that the company will post earnings of ($0.25) per share, with EPS estimates ranging from ($0.56) to $0.04. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover ViewRay.
ViewRay (NASDAQ:VRAY) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.02). The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. The firm’s revenue for the quarter was up 133.3% on a year-over-year basis. During the same period last year, the business posted ($0.32) EPS.
Several research analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on ViewRay in a report on Thursday, June 29th. They set an “overweight” rating and a $10.00 target price on the stock. Aegis reiterated a “buy” rating and set a $11.00 target price on shares of ViewRay in a report on Saturday, July 22nd. ValuEngine upgraded ViewRay from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Mizuho assumed coverage on ViewRay in a report on Wednesday, September 6th. They set a “buy” rating and a $12.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $10.00.
Hedge funds have recently bought and sold shares of the business. Nationwide Fund Advisors lifted its holdings in ViewRay by 843.2% during the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after acquiring an additional 14,789 shares in the last quarter. HighTower Advisors LLC lifted its holdings in ViewRay by 5.0% during the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after acquiring an additional 1,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in ViewRay during the second quarter worth about $159,000. Highbridge Capital Management LLC bought a new position in ViewRay during the first quarter worth about $167,000. Finally, Boston Financial Mangement LLC bought a new position in ViewRay during the first quarter worth about $170,000. Hedge funds and other institutional investors own 53.67% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/09/23/0-14-eps-expected-for-viewray-inc-vray-this-quarter.html.
Shares of ViewRay (NASDAQ VRAY) opened at 5.65 on Friday. The stock’s 50 day moving average price is $6.02 and its 200-day moving average price is $6.02. ViewRay has a 12 month low of $2.64 and a 12 month high of $6.44. The firm’s market capitalization is $333.39 million.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.